Prasugrel 5 mg in the very elderly attenuates platelet inhibition but maintains noninferiority to prasugrel 10 mg in nonelderly patients: The GENERATIONS trial, a pharmacodynamic and pharmacokinetic study in stable coronary artery disease patients

Journal of the American College of Cardiology

Volumn 62, Issue 7, 2013, Pages 577-583

  Erlinge, David ^a   Gurbel, Paul A ^b   James, Stefan ^c   Lindahl, Tomas L ^d   Svensson, Peter ^a   Ten Berg, Jurrien M ^e   Foley, David P ^f   Wagner, Henrik ^a   Brown, Patricia B ^g   Luo, Junxiang ^g   Zhou, Chunmei ^g   Moser, Brian A ^g   Jakubowski, Joseph A ^g   Small, David S ^g   Winters, Kenneth J ^g   Angiolillo, Dominick J ^h  

^a LUND UNIVERSITY   (Sweden)

^b SINAI CENTER FOR THROMBOSIS RESEARCH   (United States)

^c UPPSALA UNIVERSITY   (Sweden)

^d LINKÖPING UNIVERSITY   (Sweden)

^e ST ANTONIUS HOSPITAL   (Netherlands)

^f BEAUMONT HOSPITAL   (Ireland)

^g ELI LILLY AND COMPANY   (United States)

^h UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

coronary artery disease; elderly; platelet reactivity; prasugrel

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; CLOPIDOGREL; PRASUGREL;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLEEDING; BLOOD ANALYSIS EQUIPMENT; BLOOD CLOTTING PARAMETERS; BLOOD CLOTTING TEST; CONTROLLED STUDY; CONTUSION; CORONARY ARTERY DISEASE; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG SAFETY; DRUG TOLERABILITY; ECCHYMOSIS; EPISTAXIS; FEMALE; HEMATOMA; HEMATURIA; HUMAN; LIGHT TRANSMISSION AGGREGOMETRY; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MELENA; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PLATELET REACTIVITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; THROMBOCYTE AGGREGATION INHIBITION; UNSPECIFIED SIDE EFFECT; VASODILATOR ASSOCIATED STIMULATED PHOSPHOPROTEIN PLATELET REACTIVITY INDEX; VERY ELDERLY;

AREA UNDER THE CONCENTRATION-TIME CURVE, TIME 0 TO LAST QUANTIFIABLE CONCENTRATION ≤4 H POST-DOSE; AUC(0-T(LAST)); CAD; CORONARY ARTERY DISEASE; ELDERLY; HIGH ON-TREATMENT PLATELET REACTIVITY; HPR; LIGHT TRANSMISSION AGGREGOMETRY; LTA; MAINTENANCE DOSE; MAXIMUM PLATELET AGGREGATION; MD; MPA; NE; NONELDERLY (≥45 TO <65 YEARS OF AGE); PD; PHARMACODYNAMIC; PHARMACOKINETIC; PK; PLATELET REACTIVITY; PRASUGREL; RESIDUAL PLATELET AGGREGATION; RPA; VASODILATOR-ASSOCIATED STIMULATED PHOSPHOPROTEIN PLATELET REACTIVITY INDEX; VASP-PRI; VE; VERY ELDERLY (≥75 YEARS OF AGE);

ADMINISTRATION, ORAL; AGE FACTORS; AGED; AGED, 80 AND OVER; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; PLATELET AGGREGATION INHIBITORS; REFERENCE VALUES; SEVERITY OF ILLNESS INDEX; SINGLE-BLIND METHOD; SURVIVAL RATE; THIOPHENES; TICLOPIDINE; TREATMENT OUTCOME;

EID: 84881362012     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2013.05.023     Document Type: Article

References (12)

1. S.D. Wiviott, E. Braunwald, and C.H. McCabe Prasugrel versus clopidogrel in patients with acute coronary syndromes N Engl J Med 357 2007 2001 2015
2. J.S. Riesmeyer, D.E. Salazar, and G.J. Weerakkody Relationship between exposure to prasugrel active metabolite and clinical outcomes in the TRITON-TIMI 38 substudy J Clin Pharmacol 52 2012 789 797
3. R.E. Wrishko, C.S. Ernest, and D.S. Small Population pharmacokinetic analyses to evaluate the influence of intrinsic and extrinsic factors on exposure of prasugrel active metabolite in TRITON-TIMI 38 J Clin Pharmacol 49 2009 984 998
4. D. Erlinge, B.J. ten, and D. Foley Reduction in platelet reactivity with prasugrel 5 mg in low-body-weight patients is noninferior to prasugrel 10 mg in higher-body-weight patients: results from the FEATHER Trial J Am Coll Cardiol 60 2012 2032 2040
5. D.S. Small, R.E. Wrishko, and C.S. Ernest Effect of age on the pharmacokinetics and pharmacodynamics of prasugrel during multiple dosing: an open-label, single-sequence, clinical trial Drugs Aging 26 2009 781 790
6. J. Silvain, G. Cayla, and J.S. Hulot High on-thienopyridine platelet reactivity in elderly coronary patients: the SENIOR-PLATELET study Eur Heart J 33 2012 1241 1249
7. D.S. Small, Y.G. Li, and C.S. Ernest Integrated analysis of pharmacokinetic data across multiple clinical pharmacology studies of prasugrel, a new thienopyridine antiplatelet agent J Clin Pharmacol 51 2011 321 332
8. Efient (prasugrel) European Union summary of product characteristics 2012 Eli Lilly and Company Indianapolis, IN
9. P. Capranzano, C. Tamburino, and D. Capodanno Platelet function profiles in the elderly: results of a pharmacodynamic study in patients on clopidogrel therapy and effects of switching to prasugrel 5 mg in patients with high platelet reactivity Thromb Haemost 106 2011 1149 1157
10. D. Alexopoulos, I. Xanthopoulou, and T.E. Plakomyti Pharmacodynamic effect of prasugrel 5 mg versus clopidogrel 150 mg in elderly patients with high on-clopidogrel platelet reactivity Am Heart J 165 2013 73 79
11. P.A. Gurbel, D. Erlinge, and E.M. Ohman Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy JAMA 308 2012 1785 1794
12. M.T. Roe, P.W. Armstrong, and K.A. Fox Prasugrel versus clopidogrel for acute coronary syndromes without revascularization N Engl J Med 367 2012 1297 1309